{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:46:58Z","timestamp":1790282818670,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd004629","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2010,1,20]],"date-time":"2010-01-20T00:00:00Z","timestamp":1263945600000}}],"reference-count":81,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd004629.pub2","type":"journal-article","created":{"date-parts":[[2010,1,18]],"date-time":"2010-01-18T11:30:40Z","timestamp":1263814240000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Interferon-alpha for maintenance of follicular lymphoma"],"prefix":"10.1002","volume":"2010","author":[{"given":"Paolo","family":"Baldo","sequence":"first","affiliation":[{"name":"CRO Aviano - Centro di Riferimento Oncologico IRCCS; Pharmacy Unit, Drug Information Centre; Via Franco Gallini, 2 Aviano (PN) Friuli-Venezia-Giulia Italy 33081"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Rupolo","sequence":"additional","affiliation":[{"name":"Centro di Riferimento Oncologico - CRO Aviano (PN) Italy; Department of Medical Oncology; Aviano (PN) Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Compagnoni","sequence":"additional","affiliation":[{"name":"Instituto Mario Negri; Laboratorio per la Ricerca Clinica Oncologica; Via La Masa 19 Milan Italy 20156"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo","family":"Lazzarini","sequence":"additional","affiliation":[{"name":"CRO Aviano - Centro di Riferimento Oncologico IRCCS; Pharmacy Unit; Via Pedemontana Occidentale, 2 33081 Aviano (PN) Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bearz","sequence":"additional","affiliation":[{"name":"Centro di Riferimento Oncologico - CRO Aviano (PN) Italy; Department of Medical Oncology; Aviano (PN) Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Cannizzaro","sequence":"additional","affiliation":[{"name":"Centro di Riferimento Oncologico - CRO Aviano (PN) Italy; Gastroenterology; Aviano (PN) Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Spazzapan","sequence":"additional","affiliation":[{"name":"Centro di Riferimento Oncologico - CRO Aviano (PN) Italy; Department of Medical Oncology; Aviano (PN) Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Truccolo","sequence":"additional","affiliation":[{"name":"Centro di Riferimento Oncologico - CRO Aviano (PN) Italy; Library; Aviano (PN) Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Moja","sequence":"additional","affiliation":[{"name":"Mario Negri Institute for Pharmacological Research; Italian Cochrane Centre; Via La Masa, 19 Milan Italy 20156"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,1,20]]},"reference":[{"key":"10.1002\/14651858.CD004629.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3109\/10428199609052435","article-title":"Interferon alpha 2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival","volume":"20","author":"Aviles","year":"1996","journal-title":"Leukemia and Lymphoma"},{"issue":"11","key":"10.1002\/14651858.CD004629.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1080\/10428190410001723269","article-title":"Interferon alpha 2b as maintenance therapy improves outcome in follicular lymphoma","volume":"45","author":"Aviles","year":"2004","journal-title":"Leukemia and Lymphoma"},{"key":"10.1002\/14651858.CD004629.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.1998.16.7.2339","article-title":"Quality-of-life adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: an aid to clinical decision making","volume":"16","author":"Cole","year":"1998","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1002\/14651858.CD004629.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1200\/JCO.2000.18.10.2010","article-title":"Interferon alfa consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809","volume":"18","author":"Fisher","year":"2000","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD004629.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1200\/JCO.1998.16.1.41","article-title":"Maintenance of remission with human recombinant Interferon Alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma","volume":"16","author":"Hagenbeek","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD004629.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1089\/152581601753193887","article-title":"Chemotherapy plus interferon-alpha 2b versus chemotherapy in the treatment of follicular lymphoma","volume":"10","author":"Neri","year":"2001","journal-title":"Journal of Hematotherapy and Stem Cell Research"},{"key":"10.1002\/14651858.CD004629.pub2-BIB0007|cit7","first-page":"141","article-title":"Interferon-alfa 2b in the treatment of follicular lymphoma: Preliminary results of a trial in progress","volume":"2 Suppl 2","author":"Price","year":"1991","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1002\/14651858.CD004629.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1054\/bjoc.2001.1822","article-title":"A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma","volume":"85","author":"Rohatiner","year":"2001","journal-title":"British Journal of Cancer"},{"issue":"19","key":"10.1002\/14651858.CD004629.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJM199211053271902","article-title":"Interferon alfa combined with chemotherapy for patients with non-Hodgkin's lymphoma","volume":"327","author":"Smalley","year":"1992","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004629.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/sj.leu.2402161","article-title":"Final analysis of the ECOG I-COPA trial (E6484) in patients with non-Hodgkin's lymphoma treated with interferon alfa (IFN-alfa2a) plus an anthracycline-based induction regimen","volume":"15","author":"Smalley","year":"2001","journal-title":"Leukemia"},{"key":"10.1002\/14651858.CD004629.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1200\/JCO.1998.16.7.2332","article-title":"Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d' Etude des Lymphomes Folliculaires 86 Trial","volume":"7","author":"Solal-C\u00e9ligny","year":"1998","journal-title":"Journal of Clinical Oncology"},{"issue":"22","key":"10.1002\/14651858.CD004629.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1056\/NEJM199311253292203","article-title":"Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte","volume":"329","author":"Solal-C\u00e9ligny","year":"1993","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004629.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3109\/10428190109097655","article-title":"Cost-effectiveness of interferon alfa-2b added to chemotherapy for high-tumor-burden follicular non-Hodgkin's lymphoma","volume":"40(5-6)","author":"Wirt","year":"2001","journal-title":"Leukemia and Lymphoma"},{"issue":"4","key":"10.1002\/14651858.CD004629.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1200\/JCO.1998.16.4.1538","article-title":"Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization","volume":"16","author":"Arranz","year":"1998","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD004629.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the Groupe D'etude des Lymphomes Folliculaires","volume":"15","author":"Brice","year":"1997","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD004629.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF00207261","article-title":"Interferon alfa-2b and chlorambucil in the treatment of non-Hodgkin's lymphoma","volume":"5","author":"Chisesi","year":"1987","journal-title":"Investigational New Drugs"},{"key":"10.1002\/14651858.CD004629.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/0277-5379(91)90566-V","article-title":"Randomized study of chlorambucil (CB) compared to interferon (alfa-2b) combined with CB in low-grade non-Hodgkin's lymphoma: an interim report of a randomized study. Non-Hodgkin's Lymphoma Cooperative Study Group","volume":"27 Suppl 4","author":"Chisesi","year":"1991","journal-title":"European Journal of Cancer"},{"issue":"7","key":"10.1002\/14651858.CD004629.pub2-BIB0018|cit18","first-page":"2644","article-title":"Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin\u2019s lymphoma with rituximab and interferon-a-2a","volume":"6","author":"Davis","year":"2000","journal-title":"Clinical Cancer Research"},{"issue":"1-2","key":"10.1002\/14651858.CD004629.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3109\/10428190009054885","article-title":"A prospective randomized study of chop versus chop plus alpha-2b interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: the International Oncology Study Group NHL1 study","volume":"40","author":"Giles","year":"2000","journal-title":"Leukemia and Lymphoma"},{"issue":"15","key":"10.1002\/14651858.CD004629.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study","volume":"25","author":"Herold","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD004629.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.1998.16.5.1922","article-title":"Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German low-grade Lymphoma Study Group","volume":"16","author":"Hiddeman","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD004629.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/oxfordjournals.annonc.a058457","article-title":"CHOP-bleo plus interferon for stage IV low-grade lymphoma","volume":"4","author":"McLaughlin","year":"1993","journal-title":"Annals of Oncology"},{"issue":"12","key":"10.1002\/14651858.CD004629.pub2-BIB0023|cit23","first-page":"1484","article-title":"Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphoma","volume":"89","author":"Morris","year":"2004","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD004629.pub2-BIB0024|cit24","unstructured":"Peterson BA Petroni GR Oken MM Johnson JL Barcos M MR Copper Cyclophosphamide versus cyclophosphamide plus interferon alfa-2b in follicular low-grade lymphomas: .a preliminary report of an intergroup trial (CALGB 8691 and EST 7486) Proceeding of ASCO 1993 366"},{"key":"10.1002\/14651858.CD004629.pub2-BIB0025|cit25","unstructured":"Peterson BA Petroni GR Oken MM Johnson JL Barcos M MR Copper Cyclophosphamide versus cyclophosphamide plus interferon alfa-2b in follicular low-grade lymphomas.an intergroup phase III trial (CALGB 8691 and EST 7486) Proceedings of ASCO, Abstract 48 1997 14a"},{"issue":"13","key":"10.1002\/14651858.CD004629.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","article-title":"Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study","volume":"112","author":"Salles","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1002\/14651858.CD004629.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2006-03-013193","article-title":"Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)","volume":"108","author":"Sebban","year":"2006","journal-title":"Blood"},{"key":"10.1002\/14651858.CD004629.pub2-BIB0028|cit28","first-page":"836","article-title":"Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma","volume":"10","author":"Unterhalt","year":"1996","journal-title":"Leukemia"},{"issue":"2","key":"10.1002\/14651858.CD004629.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1600-0609.1997.tb00730.x","article-title":"Results of a fludarabine induction and alpha-interferon maintenance protocol in pretreated patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma","volume":"59","author":"Zinzani","year":"1998","journal-title":"European Journal of Haematology"},{"issue":"1","key":"10.1002\/14651858.CD004629.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00002371-200101000-00007","article-title":"Meta-analysis to assess the efficacy of interferon-alpha in patients with follicular non-Hodgkin's lymphoma","volume":"24","author":"Allen","year":"2001","journal-title":"Journal of Immunotherapy"},{"key":"10.1002\/14651858.CD004629.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1136\/bmj.319.7223.1492","article-title":"Calculating the number needed to treat for trials where the outcome is time to an event","volume":"319","author":"Altman","year":"1999","journal-title":"British Medical Journal"},{"issue":"8","key":"10.1002\/14651858.CD004629.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","article-title":"New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project","volume":"16","author":"Armitage","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD004629.pub2-BIB0033|cit33","first-page":"123","article-title":"Assessment of prognostic factors in 127 patients followed for 10 years","volume":"22 Suppl 2","author":"Bastion","year":"1991","journal-title":"Annals of Oncology"},{"issue":"2","key":"10.1002\/14651858.CD004629.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/cncr.11934","article-title":"Rapid detection of the t(11;14) translocation in mantle cell lymphoma by interphase fluorescence in situ hybridization on archival cytopathologic material","volume":"102","author":"Bentz","year":"2004","journal-title":"Cancer Cytopathology"},{"key":"10.1002\/14651858.CD004629.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0145-2126(06)80002-0","article-title":"Principles of maintenance therapy","volume":"30 Suppl 1","author":"Berinstein","year":"2006","journal-title":"Leukemia Research"},{"issue":"2-3","key":"10.1002\/14651858.CD004629.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/02841860151116286","article-title":"A systematic overview of chemotherapy effects in indolent non-Hodgkin's lymphoma","volume":"40","author":"Brandt","year":"2001","journal-title":"Acta Oncologica"},{"issue":"10","key":"10.1002\/14651858.CD004629.pub2-BIB0037|cit37","first-page":"3937","article-title":"A bcl-2\/IgH antisense transcript deregulates bcl-2 gene expression in human follicular lymphoma t(14;18) cell lines","volume":"88","author":"Capaccioli","year":"1996","journal-title":"Oncogene"},{"issue":"2","key":"10.1002\/14651858.CD004629.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ctrv.2006.10.005","article-title":"Rituximab in lymphoma: a systematic review and consensus practice guideline from Cancer Care Ontario","volume":"33","author":"Cheung","year":"2007","journal-title":"Cancer Treatment Reviews"},{"key":"10.1002\/14651858.CD004629.pub2-BIB0039|cit39","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]","author":"Higgins","year":"2008, available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD004629.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1038\/sj.onc.1210376","article-title":"Rituximab therapy in malignant lymphoma","volume":"26","author":"Coiffier","year":"2007","journal-title":"Oncogene"},{"issue":"4","key":"10.1002\/14651858.CD004629.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1200\/JCO.1993.11.4.644","article-title":"Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy","volume":"11","author":"Dana","year":"1993","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD004629.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3324\/haematol.13574","article-title":"Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols","volume":"94","author":"Jong","year":"2009","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD004629.pub2-BIB0043|cit43","doi-asserted-by":"crossref","DOI":"10.1002\/9780470693926.ch15","article-title":"Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis.","volume-title":"Egger M, Davey Smith G, Altman DG (editors). Systematic Reviews in Health Care: Meta-analysis in Context","author":"Deeks","year":"2001"},{"issue":"3","key":"10.1002\/14651858.CD004629.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD004629.pub2-BIB0045|cit45","volume-title":"Principles and Practice of Oncology","author":"DeVita","year":"2005"},{"issue":"1","key":"10.1002\/14651858.CD004629.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/bmj.309.6964.1286","article-title":"Systematic Reviews: Identifying relevant studies for systematic reviews","volume":"309","author":"Dickersin","year":"1994","journal-title":"British Medical Journal"},{"issue":"1","key":"10.1002\/14651858.CD004629.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.beha.2004.08.004","article-title":"Modern histological classification of low grade B-cell lymphomas","volume":"18","author":"Dogan","year":"2005","journal-title":"Best Practice & Research Clinical Haematology"},{"issue":"18","key":"10.1002\/14651858.CD004629.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1200\/JCO.2000.18.18.3302","article-title":"Systematic overview of cost-utility assessments in oncology","volume":"18","author":"Earle","year":"2000","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD004629.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1023\/B:HCMS.0000005397.93173.bb","article-title":"Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: A critical appraisal","volume":"7","author":"Evans","year":"2004","journal-title":"Health Care Management Science"},{"issue":"1","key":"10.1002\/14651858.CD004629.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0925-5710(96)00492-6","article-title":"Cytokine therapy for hematological malignancies","volume":"65","author":"Ezaki","year":"1996","journal-title":"International Journal of Hematology"},{"issue":"3","key":"10.1002\/14651858.CD004629.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/10428190802713513","article-title":"First-line treatment of follicular lymphoma \u2013 a patient-oriented algorithm","volume":"50","author":"Feuerlein","year":"2009","journal-title":"Leukemia & Lymphoma"},{"issue":"5","key":"10.1002\/14651858.CD004629.pub2-BIB0052|cit52","first-page":"1089","article-title":"Expression of the bcl-2 gene product in follicular lymphoma","volume":"140","author":"Gaulard","year":"1992","journal-title":"The American Journal of Pathology"},{"key":"10.1002\/14651858.CD004629.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/00031305.1995.10476135","article-title":"Comparing treatments using quality-adjusted survival. The Q-TWiST method","volume":"49","author":"Gelber","year":"1995","journal-title":"The American Statistician"},{"key":"10.1002\/14651858.CD004629.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"995","DOI":"10.7326\/0003-4819-130-12-199906150-00008","article-title":"Toward Evidence-Based Medical Statistics. 1: The P Value Fallacy","volume":"130","author":"Goodman","year":"1999","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD004629.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.5858\/1999-123-1182-MCL","article-title":"Mantle cell lymphoma: molecular and immunophenotypic diagnostic aids","volume":"123","author":"Hankin","year":"1999","journal-title":"Archives of Pathology & Laboratory Medicine"},{"issue":"5","key":"10.1002\/14651858.CD004629.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms. a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD004629.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.thj.6200013","article-title":"The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues:report of the Clinical Advisory Comittee meeting - Airlie House, Virginia, November 1997","volume":"1","author":"Harris","year":"2000","journal-title":"The Hematology Journal"},{"key":"10.1002\/14651858.CD004629.pub2-BIB0058|cit58","first-page":"13","article-title":"Interferon alfa for the treatment of follicular lymphomas","volume":"4 Suppl 2","author":"Hiddemann","year":"1998","journal-title":"The Cancer Journal from Scientific American"},{"key":"10.1002\/14651858.CD004629.pub2-BIB0059|cit59","volume-title":"Malignant lymphomas: other than Hodgkin's disease: histology, cytology, ultrastructure, immunology","author":"Lennert","year":"1978"},{"key":"10.1002\/14651858.CD004629.pub2-BIB0060|cit60","volume-title":"Histopathology of non-Hodgkin's lymphomas (based on the updated Kiel Classification) with a section on clinical therapy by M. Engelhard and G. Brittinger","author":"Lennert","year":"1992"},{"issue":"5","key":"10.1002\/14651858.CD004629.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/cncr.20483","article-title":"The role of fludarabine in the treatment of follicular and mantle cell lymphoma","volume":"101","author":"Lenz","year":"2004","journal-title":"Cancer"},{"issue":"9","key":"10.1002\/14651858.CD004629.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1182\/blood.V93.9.3081.409a43_3081_3087","article-title":"Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma","volume":"93","author":"Lopez","year":"1999","journal-title":"Blood"},{"key":"10.1002\/14651858.CD004629.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/hon.2900010209","article-title":"Criteria for the cytologic subclassification of follicular lymphomas: a proposed alternative method","volume":"1","author":"Mann","year":"1982","journal-title":"Hematological Oncology"},{"issue":"6","key":"10.1002\/14651858.CD004629.pub2-BIB0064|cit64","first-page":"364","article-title":"Prognostic significance of t(14;18) and bcl-2 gene expression in follicular small cleaved cell lymphoma and diffuse large cell lymphoma","volume":"20","author":"Martinka","year":"1997","journal-title":"Clinical and Investigative Medecine Clinique et Experimentale"},{"issue":"10","key":"10.1002\/14651858.CD004629.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1182\/blood.V88.10.3937.bloodjournal88103937","article-title":"Morphologic transformation of follicular lymphoma is associated with somatic mutation of the translocated Bcl-2 gene","volume":"88","author":"Matolcsy","year":"1996","journal-title":"Blood"},{"key":"10.1002\/14651858.CD004629.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/annonc\/8.suppl_2.S119","article-title":"Somatic mutations of the translocated bcl-2 gene are associated with morphologic transformation of follicular lymphoma to diffuse large-cell lymphoma","volume":"8 Suppl 2","author":"Matolcsy","year":"1997","journal-title":"Annals of Oncology"},{"issue":"15","key":"10.1002\/14651858.CD004629.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT Statement: revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"285","author":"Moher","year":"2001","journal-title":"The Journal of American Medicine Association"},{"key":"10.1002\/14651858.CD004629.pub2-BIB0068|cit68","doi-asserted-by":"crossref","unstructured":"The Non-Hodgkin's Lymphoma Pathologic Classification Project NHLPCP. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage Cancer 1982 2112 35","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2"},{"key":"10.1002\/14651858.CD004629.pub2-BIB0069|cit69","unstructured":"National Institute for Health and Clinica Excellence (NICE) Project Team Rituximab for the treatment of follicular lymphoma NICE Technology Appraisal Guidance 110 - www.nice.org.uk\/TA110 2006"},{"issue":"10","key":"10.1002\/14651858.CD004629.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1182\/blood.V99.10.3806","article-title":"Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3","volume":"99","author":"Ott","year":"2002","journal-title":"Blood"},{"issue":"24","key":"10.1002\/14651858.CD004629.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD004629.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/annonc\/mdm543","article-title":"The impact of follicular lymphoma on health-related quality of life","volume":"19","author":"Pettengell","year":"2008","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD004629.pub2-BIB0073|cit73","first-page":"241","article-title":"Tumors of the hematopoietic system","volume-title":"Atlas of Tumor Pathology","volume":"Fasc. 8","author":"Rappaport","year":"1966"},{"issue":"10","key":"10.1002\/14651858.CD004629.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1200\/JCO.2005.06.146","article-title":"Meta-analysis to evaluate the role of interferon in follicular lymphoma","volume":"23","author":"Rohatiner","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD004629.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1002\/14651858.CD004629.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","article-title":"Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis","volume":"99","author":"Schulz","year":"2007","journal-title":"Journal of the National Cancer Institute"},{"issue":"21","key":"10.1002\/14651858.CD004629.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1200\/JCO.2007.15.5358","article-title":"Impact of rituximab and\/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: A GELA study","volume":"26","author":"Sebban","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD004629.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1200\/JCO.1998.16.7.2332","article-title":"Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas; final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 trial","volume":"16","author":"Solal-C\u00e9ligny","year":"1998","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD004629.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular Lymphoma International Prognostic Index (FLIPI)","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"key":"10.1002\/14651858.CD004629.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0140-6736(88)90367-4","article-title":"Updated Kiel classification for lymphomas","volume":"i","author":"Stansfeld","year":"1988","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD004629.pub2-BIB0081|cit81","article-title":"Rituximab as maintenance therapy for patients with follicular lymphoma","author":"Vidal","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD004629.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:03:16Z","timestamp":1782086596000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD004629.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Haematological Malignancies Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2010,1,20]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2010,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004629.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,20]]}}}